The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Open accessAbstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“C797 is located opposite T790 in the ATP binding pocket and forms a covalent bond with all third-generation TKIs and is necessary for the inhibitor to suppress EGFR (21).”
From The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies (2015) · cites this paper as [21]
Experimental — accuracy not yet measuredIn the citing paper
“In 2009, Pasi et al. identified a series of covalent pyrimidine EGFR inhibitors, including WZ 3146, WZ 4002, and WZ 8040, through screening a library of irreversible kinase inhibitors specific to EGFRT790M.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [203]
In the citing paper
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [34]
In the citing paper
“This approach has previously led to identification of clinically relevant drug resistance mutations to EGFR TKIs (30, 31).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [30]
In the citing paper
“Thus, the T790M structural alteration in essence “enabled” discovery of inhibitors that selectively inhibit T790M–bearing mutants, when in association with L858R or exon 19 deletions, relative to WT EGFR 58,59.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [58]
In the citing paper
“Examination of the crystal structure of WZ4002 in complex with EGFR T790M (14) reveals that both L718 and L844 are in direct contact with the inhibitor; L718 primarily with the aniline ring and L844 with the pyrimidine ring (Figure 2A).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“C797 is the site of covalent binding of WZ4002 and previously demonstrated to lead to drug resistance if mutated to serine (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“However, ENU mutagenesis studies have been predictive of clinical drug resistance mutations in several prior studies (14, 24).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“In prior studies, introduction of C797S into the background of EGFR L858R/T790M or EGFR Del 19/T790M resulted in significant loss of cellular potency for WZ4002 (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Analogously, a non-covalent analogue of WZ4002, WZ4003, was ineffective in in vitro models of EGFR T790M (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“WZ4002 is a covalent pyrimidine EGFR inhibitor specifically designed against EGFR T790M that is 30–100 fold more potent against EGFR T790M, and up to 100 fold less potent against wild type EGFR than quinazoline based EGFR inhibitors in vitro and is effective in murine models of lung cancer driven by EGFR T790M [84].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [84]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [43]
In the citing paper
“Standard of care is rapidly changing with the development of third-generation, mutant-selective EGFR-TKIs that have activity against cells that harbor TKI-sensitive EGFR mutations. Unlike conventional EGFR-TKIs, this activity is maintained in the presence of T790M resistance mutation.8,9”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [9]
In the citing paper
“Next-generation EGFR TKIs have since been developed specifically to target the T790M mutation, 17,18 and they have demonstrated high and durable responses in patients with advanced EGFRmutant NSCLC who have been previously treated and in whom firstor second-generation EGFR TKIs have failed.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Self-citationBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Self-citationEngelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Niu, A., Wang, Y., Yang, Y., Wei, J., Ding, J., Chen, Y., Tong, L., & Xie, H. (2018) · Letters in Drug Design & Discovery · doi:10.2174/1570180815666180523090558 · Cited by 1
Lyu, P. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.20.003405 · Cited by 1
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 1
Malignant Epithelial Tumors of the Lung
Weissferdt, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-36438-0_12 · Cited by 1
Coiled coil control of diverse EGFR functions
Mozumdar, D., Quach, K., Doerner, A. E., & Schepartz, A. (2021) · The FASEB Journal · doi:10.1096/fasebj.2021.35.s1.03155 · Cited by 1
Xu, T., Zhang, L., Xu, S., Yang, C., Luo, J., Ding, F., Lu, X., Liu, Y., Tu, Z., Li, S., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201302313 · Cited by 1
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00008-1 · Cited by 1
Mouse Models of Receptor Tyrosine Kinases
Holcmann, M., Amberg, N., Drobits, B., Glitzner, E., Komposch, K., Robson, J., Savarese, F., Srivatsa, S., Stulnig, G., & Sibilia, M. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_11 · Cited by 1
Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine
Berger, A. H., & Pandolfi, P. P. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_27 · Cited by 1
Herreros‐Pomares, A. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/137036 · Cited by 1
Cretella, D. (2015) · DSpaceUnipr (University of Parma)
Efferth, T. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_14
Medicinal Chemistry in the Context of the Human Genome
Brunschweiger, A., & Hall, J. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch13
Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja
Discovery of Predictive Biomarkers for Anticancer Drugs
Neve, R. M., Belmont, L. D., Bourgon, R., Evangelista, M., Huang, X., Schmidt, M., Yauch, R. L., & Settleman, J. E. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch02
Regulation of EGF receptor dynamics by protein tyrosine phosphatases
Monast, C. S. (2013) · ScholarlyCommons (University of Pennsylvania)
Identificación y análisis funcional de nuevos oncogenes amplificados en cáncer de pulmón
Castillo, S. D. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Schrock, A. B. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer
Wilson, C. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s9974
Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer
Johnson, B. E., & Janne, P. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.tcme10-pl2-1
State bounds estimation for nonlinear systems using μ-analysis
Kim, J., Kishida, M., & Bates, D. G. (2014) · IFAC Proceedings Volumes · doi:10.3182/20140824-6-za-1003.01572
New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer
Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63
Ahmed, M., Sadek, M. M., Abouzid, K. A. M., & Wang, F. (2013) · arXiv (Cornell University) · doi:10.48550/arxiv.1305.6666
NOVeL treatMeNts tO OVercOMe tKI resIstaNce
Sacher, A. G. (2014)
Overcoming EGFR-TKI Resistance
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_4
Genetic and Epigenetic Determinants of Lung Cancer Subtype: Adenocarcinoma to Small Cell Conversion
Rudin, C. M. (2015) · Defense Technical Information Center (DTIC) · doi:10.21236/ada623599
The Future of Kinase Drug Discovery
Garcı́a-Echeverrı́a, C. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733557-00286
The Mechanisms and Kinetics of Protein Kinase Inhibitors
Ward, W. H. J. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733557-00096
Ebi, H., & Mitsudomi, T. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.005
Miyamoto, S., Okuma, Y., Takagi, Y., Shimokawa, T., Shimokawa, Y., Iguchi, M., Okamura, T., & Shibuya, M. (2011) · Palliative Care Research · doi:10.2512/jspm.6.119
Covalent Kinase Inhibitors for Cancer
Owens, T. D., & Lou, Y. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12399-6
Synthesis of Nitrogen-containing 4-alkoxybenzaldehyde Analogues
Xiao, Z., Tang, S., Wang, X., Zheng, P., & Xu, S. (2018) · International Conference on Biological Sciences and Technology (BST) · doi:10.2991/bst-17.2018.40
Li, F., & Kang, J. (2018) · Wiley eBooks · doi:10.1002/9781118801512.ch16
Signaling Pathways as Therapeutic Targets in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Jerchel, I. S. (2018) · RePub (Erasmus University Rotterdam)
Mitsudomi, T. (2011) · doi:10.2217/ebo.11.228
Conclusion and Future Perspectives
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00007-x
Molecular dynamic investigate the affection of EGFR by Tubemoside
Du, X., Chen, Z., Guo, D., Zhang, H., Liu, Y., Wang, C.-L., Sun, T., Shi, L.-F., Li, Y., & Liu, F. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.01.017
Targeting epidermal growth factor receptor pathway with irreversible tyrosine kinase inhibitor
Sağır, F., & Demiroglu‐Zergeroglu, A. (2019) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2017-0276
Clinical Strategies for Developing Next-Generation Cancer Precision Medicines
See, C. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-18375-2_7
Lu, X., Smaill, J. B., & Ding, K. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00182
Targeting Oncogene Addiction for Cancer Therapy
Thapa, S., Rather, R. A., Singh, S. K., & Bhagat, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101244
Applications of Constrained Helices
Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch4
Cysteinyl Proteomes: Exotic Modifications
(2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839161841-00358
Weiner, L. M., & Wu, C. S.-Y. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_27-2
Our choices from the recent literature
(2010) · Nature Chemical Biology · doi:10.1038/nchembio.328
Weiner, L. M., & Wu, C. S.-Y. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_27
(2010) · Nature reviews. Cancer · doi:10.1038/nrc2802
Shipps, G. W., & Huang, X. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.9038956.12048054
(2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3107
Les cancers bronchiques non à petites cellules EGFR-mutés
Baldacci, S., Gervais, R., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30054-x
Self-citationAhmad, I., Pawara, R. H., Pathan, A., & Patel, H. (2022) · Springer eBooks · doi:10.1007/978-981-19-0932-0_1
Synthesis and Evaluation of Celastrol Derivatives as HIF-1α Inhibitors
Ren, X., Cui, L., Wang, Y., Li, H., & Shen, G. (2022) · Chemistry of Natural Compounds · doi:10.1007/s10600-022-03870-z
Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G., Capelletti, M., et al. (2023) · doi:10.1158/0008-5472.22385378
Self-citationYoshida, T., Zhang, G., Smith, M. A., López, A. S., Bai, Y., Li, J., Fang, B., Koomen, J. M., Rawal, B., Fisher, K. J., et al. (2023) · doi:10.1158/1078-0432.c.6522212
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W. J., Ladanyi, M., & Miller, V. A. (2023) · doi:10.1158/1078-0432.c.6519458
Wang, W., Li, Q., Takeuchi, S., Yamada, T., Koizumi, H., Nakamura, T., Matsumoto, K., Mukaida, N., Nishioka, Y., Sone, S., et al. (2023) · doi:10.1158/1078-0432.c.6521184
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W. J., Ladanyi, M., & Miller, V. A. (2023) · doi:10.1158/1078-0432.c.6519458.v1
Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S. I., Ahn, M., & Park, K. (2023) · doi:10.1158/1535-7163.22498143
Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S. I., Ahn, M., & Park, K. (2023) · doi:10.1158/1535-7163.c.6535806
Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S. I., Ahn, M., & Park, K. (2023) · doi:10.1158/1535-7163.c.6535806.v1
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2023) · doi:10.1158/2159-8290.22530261
Self-citationBahcall, M., Paweletz, C. P., Kuang, Y., Taus, L. J., Sim, T., Kim, N. D., Dholakia, K. H., Lau, C. J., Gokhale, P. C., Chopade, P. R., et al. (2023) · doi:10.1158/1535-7163.c.6543231
(2023) · doi:10.1158/2159-8290.c.6549370.v1
Self-citationPotential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy
Sarkate, A. P., Bhandari, S. V., Inamdar, P. R., Kuthe, P. V., & Padvi, K. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-5281-6_7
The inhibitory effect of isavuconazole on almonertinib metabolism and its underlying mechanismPreprint
Chen, Z., Liu, Y., Xia, H., Yu, Y., & Xu, R.-A. (2024) · Research Square · doi:10.21203/rs.3.rs-4116071/v1
贾, 硕. (2024) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2024.123021
Evolving therapeutic landscape of EGFR-TKIs in NSCLC
Feng, C., Li, R., Li, X., & Xu, X. (2024) · Molecular & cellular biomechanics · doi:10.62617/mcb.v21.230
Taheri, M., Yousefi, M., Jahanban, L., Roustaei, A., Cheraghi, M., Shahriari, I., Pourtalabah, E. K., Alnoaemi, B. M., Jawhar, Z. H., & Shahcheragh, S. K. (2024) · Journal of Coordination Chemistry · doi:10.1080/00958972.2024.2404512
Shvetsov, A. B., & Semenov, A. V. (2024) · Биоорганическая химия · doi:10.31857/s0132342324060037
A case study of the irreversible covalent epidermal growth factor receptor (EGFR) inhibitor—afatinib
Yu, Y., & Chen, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00005-x
Bhanukiran, K., Gutti, G., Singh, S. K., & Chinchili, K. K. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143151
Li, S., Dong, W., & Qu, A. (2025) · Pharmaceuticals · doi:10.3390/ph18081092
Radioisotope-labeled tyrosine kinase inhibitors in the diagnosis and treatment of lung cancer
Zahid, M., Wang, H., Li, Y., & Zhang, J. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10295-9
Metabolic STAMP reveals GPCR signaling networks that program β-cell insulin secretionPreprint
Aziz‐Zanjani, M. O., Turn, R. E., Hang, Y., Asthana, A., Labrie, L. E., Mobedi, M., Xu, L. A., Ramste, A., Krawitzky, M., Knowles, J. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680349
Fujiwara, M., Baba, T., Yamada, K., Nakamura, E., Takeguchi, T., Takigawa, Y., Morita, A., Hara, N., Watanabe, H., Ninomiya, K., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6220-25
Guided by Enzymes: Targeted Photodynamic Therapy as a Strategy for Precision Medicine
Wild, L., Whitcher, J., Rossel, T., Cariou, K., & Gasser, G. (2025) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2025.838
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Chen, J., Wang, T., & Shi, L. (2026) · European Biophysics Journal · doi:10.1007/s00249-026-01823-w
BALYMBETOVA, L., Iztleuov, Y. M., Ismagulova, E. K., Kozhantayeva, S., & Balapasheva, A. (2026) · Medicine · doi:10.1097/md.0000000000047860
Seo, J., & Kim, J.-H. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112117
Ahmadabadi, M. N., Rezaee, E., Mokhtari, S., Garmabdari, A., Moghadam, M. A. J., Kobarfard, F., & Tabatabai, S. A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146499
Lin, C., Liu, J., Ni, J., Chen, D., Liu, Y., Zhu, W., Sheng, Y., Wang, Y., Gao, Y., Zhang, S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03901-x
Eck, M. J., & Scott, D. A. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0505
Self-citationNanjyo, S., & 南條, 成. (n.d.) · Institutional Repositories DataBase (IRDB)
Seidler, N. J., MacDonald, M. R., Moschopoulou, A. A., Cunningham, S., Weber, T. M., Nasief, N. N., Mayer, L., Hacker, F. W., Hermann, E., Möllers, M. B., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.2953141
Seidler, N. J., MacDonald, M. R., Moschopoulou, A. A., Cunningham, S., Weber, T. M., Nasief, N. N., Mayer, L., Hacker, F. W., Hermann, E., Möllers, M. B., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.2953141
Rahmawati, F., Habibie, R. K., Saputra, B. W., Ritmaleni, Murwanti, R., & Hermawan, A. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00823-2
Functional group-dependent stabilization and dissociation mechanisms of EGFR allosteric inhibitors
Tariq, A., Shoaib, M., Qu, L., Xiaofei, 南. N., & Song, J. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109586
From single to dual targeting: Recent advances in EGFR-based dual inhibitors for cancer therapy
YALCIN, Z. S., Alagöz, M. A., & Algül, Ö. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119400
Ansari, A., Siddique, M. U. M., & Agrawal, Y. O. (2026) · ChemistrySelect · doi:10.1002/slct.74775
Patel, A. (2026) · Journal of High School Science · doi:10.64336/001c.172802
The Intersection of Allostery and Induced Proximity through the E3 Ligase Cereblon
Dippon, V. N., & Woo, C. M. (2026) · ACS Central Science · doi:10.1021/acscentsci.6c01187
Metadata
- Authors
- Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K.-K., Eck, M. J., Gray, N. S., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Northeastern University (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Nature
- Published
- 2009-12
- Volume
- 462
- Issue
- 7276
- Pages
- 1070-1074
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2879581
- OpenAlex
- W2133963438
- Cited by
- 1,013
- References
- 30
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 46 · 2021: 55 · 2020: 62 · 2019: 55 · 2018: 66 · 2017: 84 · 2016: 82 · 2015: 75 · 2014: 71 · 2013: 82 · 2012: 54
- FWCI
- 45.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (R01AG2400401)
- National Cancer Institute (R01CA116020, R01CA122794, R01CA130876, R01CA11446, P50CA090578, R01CA135257, R01CA080942)
- National Institute of General Medical Sciences (R01GM070590)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- EGFR kinase inhibitors, mutant-selective inhibitors, irreversible kinase inhibitors, non-small cell lung cancer, drug resistance, co-crystallization, gatekeeper mutation
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Lung, Models, Chemical, Models, Molecular, Mutation, Phosphorylation, Drug Resistance, Neoplasm, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
